2018 American Transplant Congress
Target Tacrolimus Troughs and CYP3A5 Polymorphisms Do Not Predict Therapeutic Drug Exposure in African American and Caucasian Renal Transplant Recipients
Background: African American(AA) renal transplant recipients(RTR) require larger tacrolimus(TAC) doses to achieve similar troughs to Caucasians which may be due to CYP3A5 polymorphisms. TAC pharmacokinetics…2018 American Transplant Congress
Prevalence and Impact of CYP3A5 Genomic Variances on Clinical Outcomes among African-American Kidney Transplant Recipients
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC.
Introduction: Kidney transplantation in African American (AA) recipients continues to demonstrate inferior outcomes when compared with other race/ethnicities. Contributing factors encompass differences in pharmacogenomics, and…2018 American Transplant Congress
Long-Term Outcomes of Liver Transplantation in Patients with Pre-Transplant Renal Dysfunction Treated with Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus
AIM: To describe the long-term outcome of liver transplantation (LT) in patients with pre-transplant renal dysfunction treated with induction therapy and delayed reduced de novo…2018 American Transplant Congress
Tacrolimus Exposure in Human Proximal Tubule Cells Results in Differentially Increased CTGF Expression in Relation to Pharmacogenetic Variants of CYP3A5 and ABCB1
AIM: Clinical studies have demonstrated the importance of genetic variation for tacrolimus disposition and suggested a role in the development of renal fibrosis associated with…2018 American Transplant Congress
De Novo Use of Extended Released Tacrolimus (Meltdose, EnvasusR)) after OLT – Does the Colonic Resorption Influences the Outcome?
Department of Transplantation, Medical University of Vienna, Vienna, Austria.
Introduction: Immunosuppression after OLT has reached a quite high standard with an excellent evidence base. However, there is still a lack of data for the…2018 American Transplant Congress
Association of CYP3A5*3*6*7 Metabolic Composites to Tacrolimus Pharmacokinetics in African American and Caucasian Renal Transplant Recipients
Background: Interpatient variability in tacrolimus pharmacokinetics(PK) is due primarily to metabolism by cytochrome P-450 3A5(CYP3A5) isoenzymes. African Americans(AA) require higher tacrolimus doses to achieve comparable…2018 American Transplant Congress
Dehydropeptidase-Iinhibitor Reduces Tacrolimus-Induced Kidney Injury by Anti-Oxidative and Anti-Apoptotic Effect
Background:Cilastatin is an inhibitor of dehydropeptidase-I which enhances the antibacterial activity of imipenem.Dehydropeptidase I is associated with not only the metabolism of the enzyme but…2018 American Transplant Congress
Evaluation of Allergy to Tacrolimus in Kidney Transplant Candidates and Recipients with a History of Macrolide Antibiotic Allergy
Background: Tacrolimus (TAC) is considered a drug of choice for maintenance immunosuppression among kidney transplant (KTX) recipients. Because of structural resemblances between macrolide antibiotics (azithromycin,…2018 American Transplant Congress
Effect of Conversion to CTLA4Ig Treatment on Tacrolimus-Induced Diabetic Rats
Background: The effect of conversion to cytotoxic T-lymphocyte-associated protein 4 immunoglobulin (CTLA4Ig) treatment on tacrolimus (TAC)-induced renal dysfunction is well known, but its effect on…2018 American Transplant Congress
The Study of the Influence on hIAPP Deposition and Dysfunction in INS-1 Cell by Calcineurin Inhibitors
Background hIAPP is formed in islet β cells, misfolded hIAPP results in the deposition inside the β-cells and shows a damage to the β-cells. The…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »